Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, China.
Expert Rev Proteomics. 2011 Aug;8(4):439-42. doi: 10.1586/epr.11.42.
Evaluation of: Rajpal R, Dowling P, Meiller J et al. A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. Proteomics 11(8), 1391-1402 (2011). Predicting response to thalidomide-based therapy remains a challenging task faced by clinicians in the treatment of multiple myeloma. The pioneering work reported by Rajpal et al. moves one step further towards solving this challenge. They developed a proteomics-based approach that combines immunodepletion, 2D-difference gel electrophoresis analysis and mass spectrometry to search for serum proteins with expressions that show significant correlations to thalidomide treatment. This integrated approach allowed them to identify a panel of protein biomarkers. By using ELISA-based validation and strict statistical analysis, the authors have achieved an overall 84.0% predictive accuracy, with associated sensitivity and specificity values of 81.8 and 86.2%, respectively. Their methods and significant findings are reviewed within this article. This panel of biomarkers may not only guide initial therapy, but can also provide direct implications for personalized medicine in multiple myeloma patients.
Rajpal R、Dowling P、Meiller J 等人。一种用于预测新诊断多发性骨髓瘤患者对沙利度胺为基础的治疗反应的新型蛋白质生物标志物。蛋白质组学 11(8), 1391-1402 (2011)。预测对沙利度胺为基础的治疗的反应仍然是临床医生在治疗多发性骨髓瘤时面临的一项具有挑战性的任务。Rajpal 等人的开创性工作在解决这一挑战方面又迈进了一步。他们开发了一种基于蛋白质组学的方法，结合免疫沉淀、2D-差异凝胶电泳分析和质谱法，寻找与沙利度胺治疗有显著相关性的血清蛋白表达。这种综合方法使他们能够识别出一组蛋白质生物标志物。通过使用 ELISA 验证和严格的统计分析，作者实现了总体 84.0%的预测准确性，相关的敏感性和特异性值分别为 81.8%和 86.2%。本文综述了他们的方法和重要发现。该生物标志物组合不仅可以指导初始治疗，还可以为多发性骨髓瘤患者的个体化医学提供直接影响。
